MEDINDIA
English
हिन्दी
Español
français
中文
Email
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Methyl aminolevulinate.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Methyl aminolevulinate.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Methyl aminolevulinate.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Methyl aminolevulinate.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methyl aminolevulinate.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Methyl aminolevulinate.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Methyl aminolevulinate.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Methyl aminolevulinate.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Methyl aminolevulinate.
Digoxin
Digoxin may decrease the cardiotoxic activities of Methyl aminolevulinate.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Methyl aminolevulinate.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Methyl aminolevulinate.
Ouabain
Ouabain may decrease the cardiotoxic activities of Methyl aminolevulinate.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Methyl aminolevulinate.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyl aminolevulinate.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Methyl aminolevulinate.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Methyl aminolevulinate.
